The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of pathogenic germline variants in pancreatic cancer: Results from a multicenter prospective universal genetic testing study.
 
Pedro Luiz Serrano Uson Junior
No Relationships to Disclose
 
Douglas Riegert-Johnson
Research Funding - Janssen
 
Lisa A. Boardman
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Daniel H. Ahn
Consulting or Advisory Role - Celltrion (I); Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Douglas O Faigel
No Relationships to Disclose
 
Norio Fukami
Consulting or Advisory Role - Boston Scientific; Creo; Olympus
 
Rahul Pannala
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - HCL Technologies; Nestle Health Science
 
Katie Kunze
No Relationships to Disclose
 
Michael A Golafshar
No Relationships to Disclose
 
Edward D. Esplin
Employment - Invitae
Stock and Other Ownership Interests - Invitae
 
Robert Luke Nussbaum
Employment - Invitae
Leadership - Invitae
Stock and Other Ownership Interests - Genome Medical; Invitae; Maze Therapeutics; Pfizer Pharmaceutical
Honoraria - Pfizer
Consulting or Advisory Role - Genome Medical; Maze Therapeutics; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties on a patented mouse model for Parkinson disease held by the National Institutes of Health and the University of California San Francisco
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Jewel Samadder
Consulting or Advisory Role - Cancer Prevention Pharmaceuticals; Janssen Research & Development